Inhibition of the TPL2-MKK1/2-ERK1/2 pathway has cytostatic effect on B-Cell Lymphoma
M. Asslan, G. Martel, S. Rousseau
This study shows that inhibiting the TPL2-MKK1/2-ERK1/2 pathway has a cytostatic effect on DLBCL cells, with potential for combination therapy.
bioRxiv · Jun 13, 2022 · PreprintPharmacology & Toxicology